Valeant; generics by Mylan and Taro) or 2% or 5% solution by Solco and Taro) on nonfacial areas twice daily until erosion occurs, usually 2–4 wk Imiquimod Toll-like Milder Recommended Less frequent receptor agonist erythema than use is limited to dosing (1–2 2.5% or (TLR-7, TLR-8); 5FU AK on the head times per wk) of 3.75% induction of 5% cream may cream Relatively Erythema, edema, proinflammatory improve short duration erosion/ulceration, cytokins; Th-1 tolerability by of therapy with exudate, antitumor Valeant): 3.75% cream scabbing/crusting, Shorter courses response; once pain, pruritus of 5% upregulation of Lower daily to treatment with a apoptosis incidence of Severe either treatment-free erosion/ulceration the interval may in 9%–11% of pts entire also be adverse using 2.5% or face or effective for events with 3.75% cream balding nonhypertrophic 3.75% cream scalp for AK. Flu-like symptoms than 5% two 2- cream applied 5% cream week Lymphadenopathy for 16 wk application is was seen in limited to a cycles of patients; Low 1-y contiguous 25 resolves by 4 wk recurrence cm2 area by a after end of tx rates (whereas the lower strengths Suggested have no topical tx limitation on alternative for period size of AK in 5% application organ cream area). transplant recipients by Valeant; generics by Taro, Perrigo, Sandoz and Global Pharma Corp.): apply to
Valeant; generics by Mylan and Taro) or 2% or 5% solution by Solco and Taro) on nonfacial areas twice daily until erosion occurs, usually 2–4 wk Imiquimod 2.5% or 3.75% cream by Valeant): once daily to either the entire face or balding scalp for two cycles by a period 5% cream by Valeant; generics by Taro, Perrigo, Sandoz and Global Pharma Corp.): apply to Toll-like receptor agonist (TLR-7, TLR-8); induction of proinflammatory cytokins; Th-1 antitumor response; upregulation of apoptosis Milder erythema than 5FU Relatively short duration of therapy with 3.75% cream Lower incidence of adverse events with 3.75% cream than 5% cream applied for 16 wk Low 1-y recurrence rates Suggested topical tx alternative for AK in organ transplant recipients Recommended use is limited to AK on the head Erythema, edema, erosion/ulceration, exudate, scabbing/crusting, pain, pruritus Severe erosion/ulceration in 9%–11% of pts using 2.5% or 3.75% cream Flu-like symptoms Lymphadenopathy was seen in of patients; resolves by 4 wk after end of tx Less frequent dosing (1–2 times per wk) of 5% cream may improve tolerability Shorter courses of 5% treatment with a treatment-free interval may also be effective for nonhypertrophic AK. 5% cream application is limited to a contiguous 25 cm2 area (whereas the lower strengths have no limitation on size of application area). week 2-